Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis.
Pei-Jun TangXingnian ChenJunchi XuYunlong HuZhijian YeXiafang WangYumei XiaoXinghua ShenJianping ZhangYanjun FengCuilin ShiXin YuLixian YiXinchun ChenBinfeng LuPing XuZhongwen SunMeiying WuPublished in: Journal of immunology research (2022)
Our study has provided strong evidence that CIK immunotherapy in combination with anti-TB chemotherapy is beneficial for MDR-TB patients. A multicenter clinical trial is warranted to evaluate CIK as a new immune therapy for MDR-TB.
Keyphrases
- multidrug resistant
- mycobacterium tuberculosis
- clinical trial
- end stage renal disease
- drug resistant
- acinetobacter baumannii
- gram negative
- ejection fraction
- chronic kidney disease
- locally advanced
- cell therapy
- single cell
- high glucose
- prognostic factors
- double blind
- klebsiella pneumoniae
- peritoneal dialysis
- bone marrow
- stem cells
- cross sectional
- pulmonary tuberculosis
- diabetic rats
- squamous cell carcinoma
- oxidative stress
- radiation therapy
- emergency department
- hiv aids
- mesenchymal stem cells
- phase ii
- electronic health record
- human immunodeficiency virus
- hiv infected